Previous 10 | Next 10 |
2023-11-13 23:41:22 ET Summary Anavex's Alzheimer's drug Blarcamesine demonstrates strong statistical significance in improving cognition among dementia patients as measured by one co-primary endpoint and one secondary endpoint. For the other co-primary endpoint, it seems the drug...
NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders,...
2023-10-25 15:18:01 ET More on Anavex Life Sciences Anavex: The September Data Anavex: Additional P2b/3 Alzheimer's Trial Data Raises Additional Questions Anavex Life Sciences Corp. (AVXL) Q3 2023 Earnings Call Transcript Alzheimer's drug developers get lift ...
ANAVEX ® 3-71 treatment prevents cognitive impairment, reduces amyloid, and neuroinflammation even after a long drug washout ANAVEX ® 3-71 halts neurodegeneration and prevents cognitive decline in a transgenic Alzheimer’s disease model Confirmation of An...
2023-10-09 11:37:28 ET Summary Anavex Life Sciences Corp. presented follow-on data from its Alzheimer’s disease trial. This data uses a statistical methodology that is difficult to understand. It appears that the trial, despite the claims, was not successful. ...
2023-09-18 08:16:42 ET SeqLL ( NASDAQ: SQL ) +70% . TradeUP Acquisition ( UPTD ) +11% . Tian Ruixiang Holdings ( TIRX ) +11% . Virios Therapeutics ( VIRI ) +9% terminates at-the-market sales agreement. Village Farms Inter...
2023-09-15 09:56:55 ET Summary On Thursday, Sep 14, Anavex Life Sciences released additional data from their phase 2b/3 Alzheimer's Disease trial. The company stated that (after a new post hoc analysis), the trial showed statistically significant results in one primary endpoint (A...
2023-09-14 13:02:36 ET More on Alzheimer's drug developers Cassava Sciences: Insiders Purchasing Stock, Is The Market Still Buying Simufilam? Prothena: Dunn Appointment And Bristol Opt-In Boost Validation Anavex Life Sciences: Multiple CNS Shots On Goal Awaiting Conv...
2023-09-14 07:59:22 ET More on Anavex Life Sciences Anavex Life Sciences: Multiple CNS Shots On Goal Awaiting Convincing Data Anavex: Will Be An Interesting Endgame To Watch Anavex lead candidate shows promise for Rett syndrome Anavex taps Partex to use AI fo...
NEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders...
News, Short Squeeze, Breakout and More Instantly...
Anavex Life Sciences Corp. Company Name:
AVXL Stock Symbol:
NASDAQ Market:
Anavex Life Sciences Corp. Website:
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsyc...
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsyc...
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announced an update in the lawsuit that is pending for certain investors in Anavex Life Sciences Corp. (NASDAQ: AVXL) shares. Investors, who purchased Anavex Life Sciences Corp. (NASDAQ: AVXL) shares prior to Februa...